| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $63.7M | +5.2% | +112.8% |
| SG&A Expense | $15.0M | +30.9% | +104.8% |
| Operating Income | -$122.1M | -71.7% | -9.7% |
| Pre-tax Income | -$116.2M | -69.2% | -5.6% |
| Income Tax | $0 | — | +100.0% |
| Net Income | -$116.2M | -69.2% | -6.0% |
| EPS (Basic) | -$1.11 | -68.2% | +85.3% |
| EPS (Diluted) | -$1.11 | -68.2% | +85.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $448.5M | -15.5% | — |
| Current Assets | $461.4M | -14.2% | — |
| Total Assets | $567.6M | -11.3% | — |
| Current Liabilities | $108.5M | +6.0% | — |
| Total Liabilities | $230.5M | +21.0% | — |
| Stockholders' Equity | $337.2M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$195.1M | — | — |
| Capital Expenditures | $198K | — | — |
| Investing Cash Flow | -$198K | — | — |
| Financing Cash Flow | $287.5M | — | — |
| Free Cash Flow | -$195.3M | — | — |
| -24.9% |
| +271.4% |